<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732405</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004713-24</org_study_id>
    <nct_id>NCT02732405</nct_id>
  </id_info>
  <brief_title>Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis</brief_title>
  <acronym>GECOM</acronym>
  <official_title>A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis (Child-Pugh A5 to A6) and No Response to PR or Prior Failure to First Generation Protease Inhibitors (PIs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CD Pharma Group S.r.l.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess efficacy (SVR rate) of MK5172 / MK8742 for 12 weeks without RBV in G1b patients
      with compensated cirrhosis (Child-Pugh A5 to A6) previously failing first gen. PI or non
      responders to PR.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response rates 12 weeks after discontinuation of therapy (SVR12). SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</measure>
    <time_frame>12 weeks after discontinuation of therapy (SVR12).</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Compensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MK5172 /MK8742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK5172 /MK8742</intervention_name>
    <description>tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin</description>
    <arm_group_label>MK5172 /MK8742</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent form signed,

          2. Age &gt; 18 years,

          3. Chronic infection with Hepatitis C virus genotype 1b,

          4. HCV RNA &gt; 100 IU/mL,

          5. HCV patients previously treated by PR with no response or previously treated with
             first generation PIs (boceprevir, telaprevir, simeprevir) and failing therapy,

          6. Subjects with compensated cirrhosis with Child-Pugh score ranging between A5 to A6.
             Cirrhosis defined by liver biopsy (METAVIR F4) or non-invasive methods (transient
             elastography (FibroScan) &gt; 12.5 KPa; or FibroTest or FibroSure &gt; 0.75 with APRI &gt;2),

          7. Hepatic Venous Pressure Gradient (HVPG) &gt; 6 mmHg (only in selected sites),

          8. Albumin level ≥ 3.0 g/dl,

          9. Platelet count ≥ 75 x 103/μL.

        Exclusion Criteria:

          1. Child-Pugh score greater than CP-A6,

          2. Patients with HCV genotype 1a, 2, 3, 4, 5, 6,

          3. Have any serious or active medical illness which, in the opinion of the investigator,
             would interfere with subject treatment, assessment, or compliance,

          4. HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive),

          5. Decompensated cirrhosis/previous decompensation,

          6. Pregnancy,

          7. Breast-feeding,

          8. Known hypersensitivity to Grazoprevir, Elbasvir or any of its components,

          9. Albumin level &lt; 3.0 g/dl,

         10. Platelet count &lt; 75 x 103/μl,

         11. Concomitant participation in any clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Savino Bruno, MD</last_name>
    <email>savino.bruno@hunimed.eu</email>
  </overall_contact>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

